The role of BDNF in the antidepressant effects of electroconvulsive therapy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Electroconvulsive therapy (ECT) is an effective treatment method for depression therapy. It produces a number of biological effects, including neurotrophic factors regulation. In the present paper, we investigated the ECT response in depressed rats subjected to the variable frequency ultrasound (20–45 kHz) and examined the contribution of brain-derived neurotrophic factor (BDNF) expression changes to the observed effects. The obtained results reflect the therapeutic potential of ECT for the treatment of depressive-like state in rodents and indicate the role of BDNF in these processes. In the future research, it is necessary to investigate the relationship between neurotrophin and structural changes and to study other neurotrophic biomarkers that may be associated with the development of depression-like state and the therapy response.

About the authors

V. M. Ushakova

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health; Lomonosov Moscow State University

Author for correspondence.
Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology, Department of Higher Nervous Function

Russian Federation, Moscow; Moscow

E. A. Zubkov

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

A. Y. Morozova

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

K. A. Pavlov

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

Y. A. Zorkina

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

O. V. Abramova

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

A. G. Ochneva

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

O. I. Gurina

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Corresponding Member of RAS, Department of Basic and Applied Neurobiology

Russian Federation, Moscow

K. S. Tarkovskaya

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health

Email: ushakovavm@yandex.ru

Department of Basic and Applied Neurobiology

Russian Federation, Moscow

A. N. Inozemtsev

Lomonosov Moscow State University

Email: ushakovavm@yandex.ru

Department of Higher Nervous Function

Russian Federation, Moscow

V. P. Chekhonin

V. Serbsky National Medical Research Centre of Psychiatry and Narcology under the RF Ministry of Public Health; The Russian National Research Medical University named after N.I. Pirogov

Email: ushakovavm@yandex.ru

Academician of the RAS, Department of Basic and Applied Neurobiology, Department of Medical Nanobiotechnologies

Russian Federation, Moscow; Moscow

References

  1. Malhi G.S., Mann J.J. Depression // Lancet. 2018. Vol. 392. P. 2299–2312.
  2. Kellner C.H., Kaicher D.C., Banerjee H., et al. Depression severity in electroconvulsive therapy (ECT) versus pharmacotherapy trials // The journal of ECT. 2015 Vol. 31. P. 31–33.
  3. Kritzer M.D., Peterchev A.V., Camprodon J.A. Electroconvulsive Therapy: Mechanisms of Action, Clinical Considerations, and Future Directions // Harvard review of psychiatry. 2023. Vol. 31, N 3. P. 101–113.
  4. Réus G.Z., de Moura A.B., Borba L.A., et al. Strategies for Treatment-Resistant Depression: Lessons Learned from Animal Models // Molecular neuropsychiatry. 2019. Vol. 5, N 4. P. 178–189.
  5. Subramanian S., Lopez R., Zorumski C.F., et al. Electroconvulsive therapy in treatment resistant depression // Journal of the neurological sciences. 2022. Vol. 434:120095.
  6. Maffioletti E., Carvalho Silva R., Bortolomasi M., et al. Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future // Brain sciences. 2021. Vol. 11, N 9: 1120.
  7. Ушакова В.М., Зубков Е.А., Морозова А.Ю., и др. Влияние электросудорожной терапии на когнитивные функции крыс при депрессивно-подобном состоянии // Бюллетень экспериментальной биологии и медицины. 2017. Т. 163. № 5. С. 549–552.
  8. Морозова А.Ю., Зубков Е.А., Кошкин Ф.А., и др. Экспрессия генов, кодирующих серотониновые рецепторы и SERT в различных структурах мозга у стрессированных хроническим воздействием ультразвука крыс // Бюллетень экспериментальной биологии и медицины. 2013. Т. 156. № 9. С. 291–294.
  9. Chen F., Danladi J., Wegener G., et al. Sustained Ultrastructural Changes in Rat Hippocampal Formation After Repeated Electroconvulsive Seizures // The international journal of neuropsychopharmacology. 2020. Vol. 23, N7. P. 446–458.
  10. Giacobbe J., Pariante C.M., Borsini A. The innate immune system and neurogenesis as modulating mechanisms of electroconvulsive therapy in pre-clinical studies // Journal of psychopharmacology (Oxford, England). 2020. Vol. 34, N10. P. 1086–1097.
  11. Kowiański P., Lietzau G., Czuba E., et al. BDNF: A Key Factor with Multipotent Impact on Brain Signaling and Synaptic Plasticity // Cellular and molecular neurobiology. 2018. Vol. 38, N3. P. 579–593.
  12. Duman R.S., Deyama S., Fogaça M.V. Role of BDNF in the pathophysiology and treatment of depression: Activity-dependent effects distinguish rapid-acting antidepressants // The European journal of neuroscience. 2021. Vol. 53, N1. P. 26–139.
  13. Björkholm C., Monteggia L.M. BDNF – a key transducer of antidepressant effects // Neuropharmacology. 2016. Vol. 102. P. 72–79.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Russian Academy of Sciences